Perspectum and BluMaiden Biosciences Pte. Ltd. (“BluMaiden BioSciences”) Form Strategic Collaboration to Introduce Novel Insights into Clinical Trials
- April 13, 2023
San Francisco, CA – April. 13, 2023. Perspectum is proud to announce a strategic collaboration with Singapore-based BluMaiden Biosciences. Developed to identify biomarkers and small molecule therapeutics from within the human microbiome, BluMaiden Bioscience’s platform-based AI technologies will be offered alongside Perspectum's medical imaging solutions. The collaboration is aimed at transforming the pharmaceutical clinical trial space in the fields of liver disease and microbiome.
Perspectum’s CEO Dr. Rajarshi Banerjee said about the collaboration, "We are thrilled to partner with BluMaiden Biosciences to tackle the growing field of microbiome research.” Dr. Banerjee added, "Our collaboration has great potential to bring new innovations to market that will ultimately benefit patients and health care professionals alike."
Together, Perspectum and BluMaiden Biosciences will combine their expertise in medical imaging and microbiome analysis to develop cutting-edge end-to-end solutions for the assessment and management of liver-related diseases like Nonalcoholic Steatohepatitis (NASH). The inclusion of microbiome analysis to clinical trials from BluMaiden Biosciences’ high-quality data and analytics platforms can lead to improvements in clinical trial outcomes and enhance the potential of microbiome-derived biomarkers in areas such as patient treatment, identification of drug responders and non-responders, and the prediction of drug efficacy and safety.
"BluMaiden Biosciences is proud to partner with Perspectum to bring our scalable new solutions to the global clinical trial space,” said Dr. Damien Keogh, CEO and Director of BluMaiden. Dr. Keogh added, "We believe that our collaboration with Perspectum will accelerate the development of these solutions."
Perspectum, a global medical technology company with offices in the US, the UK, Portugal, and Singapore, delivers leading digital technologies that help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathology, and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale. For additional information, please visit: Perspectum.com and LinkedIn
About BluMaiden Biosciences
BluMaiden Biosciences is a small-molecule drug discovery company with advanced AI microbiome analysis platforms. Headquartered in Singapore but with a globally deployable cloud-based analytics system, the company is committed to advancing the field of microbiome research through cutting-edge solutions that improve the diagnosis and treatment of disease. With a focus on innovation and quality, BluMaiden is dedicated to improving patient outcomes through advanced microbiome analysis. For additional information, please visit: Blumaiden.com and LinkedIn
VP Corporate Affairs Perspectum